VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,732,168 | +16.0% | 92,824 | +13.6% | 0.00% | +50.0% |
| Q2 2023 | $4,079,549 | +275.8% | 81,689 | +182.1% | 0.00% | +100.0% |
| Q1 2023 | $1,085,421 | -20.6% | 28,960 | +1.6% | 0.00% | 0.0% |
| Q4 2022 | $1,366,431 | +174.5% | 28,497 | +37.4% | 0.00% | – |
| Q3 2022 | $497,832 | +10.2% | 20,743 | -0.1% | 0.00% | – |
| Q2 2022 | $451,651 | +6.8% | 20,756 | +18.5% | 0.00% | – |
| Q1 2022 | $422,842 | -17.3% | 17,509 | -18.5% | 0.00% | – |
| Q4 2021 | $511,000 | -5.7% | 21,480 | +0.5% | 0.00% | – |
| Q3 2021 | $542,000 | +5.2% | 21,379 | -6.6% | 0.00% | – |
| Q2 2021 | $515,000 | +56.5% | 22,888 | +37.6% | 0.00% | – |
| Q1 2021 | $329,000 | +10.0% | 16,639 | +47.8% | 0.00% | – |
| Q4 2020 | $299,000 | -39.2% | 11,260 | +13.0% | 0.00% | -100.0% |
| Q3 2020 | $492,000 | – | 9,963 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |